BCL2 and hematopoietic and lymphoid cell neoplasm: Targeting BCL-2 through venetoclax is an effective therapy for a series of hematological cancers, such as mantle cell lymphoma (MCL), but resistance to venetoclax is an increasing challenge that needs to be overcome.